When you’ve seen 1 Parkinson’s patient,
you’ve seen 1
Parkinson’s patient
Are we doing everything to meet their unique needs?
When you’ve seen 1 Parkinson’s patient, you’ve seen 1 Parkinson’s patient
Are we doing everything to meet their unique needs?
Patients with Parkinson’s disease (PD) have 1 thing in
common:
the burden they face is significant
common: the burden they face is significant
- PD Parkinson’s disease affects nearly 1 million people in the United States1,2
- There are 60,000 new cases of PD diagnosed each year3
- Parkinson’s disease is the fastest-growing neurological disorder4
MORE THAN MOTOR SYMPTOMS
DISEASE PROGRESSION IS INEVITABLE
DIAGNOSIS IS DEVASTATING
Current treatments do little to address the variable
nature of Parkinson’s disease5
nature of Parkinson’s disease5
FOR ALMOST 50 YEARS, CD/LD HAS BEEN THE GOLD STANDARD FOUNDATIONAL TREATMENT FOR PD2,7,8
- Many CD/LD patients report difficulty managing OFF time and side effects, including dyskinesia2,9
- Newer formulations can be complicated and have low patient satisfaction6
- As PD progresses, the therapeutic window narrows and motor complications (dyskinesia and OFF-time symptoms) occur6,10
DOSING STRATEGIES WITH CURRENT CD/LD TABLETS PUT PATIENTS AT RISK OF IMPRECISE DOSING
- People with Parkinson’s disease may bite, chew, or use methods other than pill splitters for partial doses of PD medications
- Loss of tablet may occur during the pill-splitting process11
- Dose inaccuracy may be a result of inaccurate splitting, leading to underdosing or overdosing11
- There is limited evidence available on dose accuracy associated with splitting11
- CD/LD=carbidopa/levodopa.
Patients with Parkinson’s disease need a better
way to
personalize their treatment
way to personalize their treatment
Patients don’t always adhere to their daily prescribed amount of CD/LD
They may be splitting their CD/LD tablets to suit their unique needs11
When this happens, they put themselves at risk of taking too much or too little CD/LD11
People with PD are looking for a way to take control of their daily doses
AVION PHARMACEUTICALS IS COMMITTED TO HELPING THE PARKINSON’S DISEASE COMMUNITY FACE A BRIGHTER FUTURE
Sign up for updates from Avion Pharmaceuticals
How can Avion help you face the future of Parkinson’s?
PATIENT TESTIMONIAL TITLE
Brief description about the patient could go here.
PATIENT TESTIMONIAL TITLE
Brief description about the patient could go here.
References: 1. Yang W, Hamilton JL, Kopil C, et al. Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinsons Dis. 2020;6:15. doi:10.1038/s41531-020-0117-1. 2. Tanner CM. Exploring the clinical burden of OFF periods in Parkinson disease. Am J Manag Care. 2020;26(12 suppl):S255-S264. doi:10.37765/ajmc.2020.88517. 3. Parkinson’s Foundation. Statistics. Accessed August 17, 2021. www.parkinson.org/understanding-parkinsons/statistics. 4. Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3-S8. doi:10.3233/JPD-181474. 5. Stoker TB, Greenland JC, eds. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications; 2018. 6. Jankovic J, Tan EK. Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795-808. doi:10.1136/jnnp-2019-322338. 7. Olanow CW, Calabresi P, Obeso JA. Continuous dopaminergic stimulation as a treatment for Parkinson’s disease: current status and future opportunities. Mov Disord. 2020;35(10):1731-1744. doi:10.1002/mds.28215. 8. Tolosa E, Martí MJ, Valldeoriola F, Molinuevo JL. History of levodopa and dopamine agonists in Parkinson’s disease treatment. Neurology. 1998;50(6 suppl 6):S2-S10. doi:10.1212/wnl.50.6_suppl_6.s2. 9. Cabreira V, Soares-da-Silva P, Massano J. Contemporary options for the management of motor complications in Parkinson’s disease: updated clinical review. Drugs. 2019;79(6):593-608. doi:10.1007/s40265-019-01098-w. 10. Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol. 2018;16(8):1239-1252. doi:10.2174/1570159X15666170510143821. 11. Chaudhri K, Kearney M, Di Tanna GL, Day RO, Rodgers A, Atkins ER. Does splitting tablet obtain the accurate dose?: a systematic review protocol. Medicine (Baltimore). 2019;98(42):e17189. doi:10.1097/MD.0000000000017189.
